| BCBS Florida Coverage Guidelines | Granulocyte Colony Stimulating Factors (09-J0000-62) | 2026-07-01 |
| BCBS Florida Coverage Guidelines | Guselkumab (Tremfya®) Injection and (09-J2000-87) | 2026-07-01 |
| UHC UMR Medical and Drug | Home Health, Skilled, and Custodial Care Services – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| BCBS Iowa Medical Policies | Bio-Engineered Skin and Soft Tissue Substitutes | 2026-07-01 |
| UHC UMR Medical and Drug | Natalizumab (Tyruko® & Tysabri®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Natalizumab (Tyruko® & Tysabri®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Beds and Mattresses – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Carrier Testing Panels for Genetic Diseases – Commercial and Individual Exchange Medical Policy | 2026-07-01 |